NLS biotech-1

The two companies have announced a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb. These will be used to develop a diagnostic test to identify tumors that express KK-LC-1. Patients with KK-LC-1 positive tumors may be eligible inclusion in clinical trials of a KK-LC-1 targeted T-Cell therapy, state the companies. “We […]

Cantargia has announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has issued a positive opinion for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer. The European Commission is now expected to grant the orphan designation. This provides a range of incentives in the continued clinical development […]

Salipro Biotech enters into a collaboration and license agreement with AbCellera for access to the Salipro platform for antibody discovery against GPCRs, ion channels, and transporters. The collaboration enables AbCellera to access Salipro Biotech’s expertise and its Salipro platform technology to generate stable antigens for challenging membrane protein drug targets for antibody discovery, the company […]

CombiGene and Spark Therapeutics have announced the signing of an exclusive collaboration and licensing agreement for CombiGene’s CG01 project, a gene therapy which aims to treat drug resistant focal epilepsy. The agreement provides Spark Therapeutics with the exclusive world-wide license to develop, manufacture and commercialize CG01. CombiGene will continue to execute certain aspects of the […]

Xbrane Biopharma and AGC Biologics, a global Biopharmaceutical CDMO, have entered into an agreement to manufacture Xcimzane, a Cimzia biosimilar candidate, for clinical development. Under terms of the agreement, the companies will work together to upscale the established Xcimzane manufacturing process and produce several commercial scale batches for upcoming phase I and phase III clinical […]

SmartCella Holding has announced the raising to further advance and accelerate the development of core technologies in the company’s three business units, Procella Therapeutics, Smartwise and SvedMed Solutions. The financing, led by advisor SEB, brings together a renowned group of investors with AMF, SEB Pension, Alto Cumulus and Celox joining existing investors including AP4 and […]